PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma to Announce Third Quarter 2016 Financial Results on November 3, 2016
PDL BioPharma Announces the Successful Conclusion of its Debt Financing Agreement with Paradigm Spine
PDL BioPharma Announces Second Quarter 2016 Financial Results
PDL BioPharma Announces Elimination of Quarterly Cash Dividend
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals